---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031670"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:09:38.759765+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RenovoRx reports Q3 net loss of $2.1M; cash at $8.1M; Phase III interim analysis expected Q4 2022

## Summary
- Net loss of $2.1 million for Q3 2022, up from $1.5 million in Q3 2021.
- Cash and short-term marketable securities of $8.1 million as of Sep 30, 2022; 9.07M shares outstanding.
- G&A expenses rose to $1.3M from $0.6M, driven by post-IPO support and D&O insurance premiums.
- Expects first prospective interim analysis of Phase III TIGeR-PaC trial in pancreatic cancer in Q4 2022.
- Plans to launch Phase II/III trial in extrahepatic cholangiocarcinoma in Q4 2022/Q1 2023; appointed Angela Gill Nelms as COO.

## SEC filing metadata
- accession: 0001493152-22-031670
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315222031670/0001493152-22-031670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315222031670/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031670
- JSON: https://secwatch.observer/filing/0001493152-22-031670.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031670.txt

## Key facts
- Earnings Releases
  RenovoRx, Inc. reported the quarter ended September 30, 2022 results: net income $2.1 million.
  - Period: the quarter ended September 30, 2022
  - Net income: $2.1 million
  - Result: reported results
  source text: Net loss was $2.1 million for the quarter ended on September 30, 2022, compared to a net loss of $1.5 million for Q3 ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574094/000149315222031670/0001493152-22-031670-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.